Safeguarding Vulnerability: COVID-19's Impact on Immunocompromised Patients With Cancer.

Abstract

The COVID-19 pandemic has exposed significant vulnerabilities among patients who are immunocompromised, who remain at increased risk for severe disease despite widespread vaccination in the general population. This commentary reviews insights from Dorry L. Segev's, MD, PhD, keynote lecture at MedNews Week, highlighting reduced vaccine efficacy, prolonged viral shedding, and increased severity of COVID-19 in this population. Emerging strategies such as monoclonal antibody prophylaxis, oral antivirals, personalized vaccine approaches, and T cell-based therapies show promise in mitigating these risks. Additionally, the commentary discusses the implications of hybrid immunity and the potential for within-host viral evolution to generate resistant variants, underscoring the need for targeted genomic surveillance. Ethical considerations are raised regarding the use of advanced oncologic treatments with marginal survival benefits but substantial toxicity in the context of COVID-19 vulnerability. To effectively protect immunocompromised patients, tailored public health measures, dedicated vaccination programs, and integrative lifestyle interventions are required. Synergistic efforts among clinicians, researchers, and policy makers are essential to ensure equitable access to preventive and therapeutic strategies, strengthening health care resilience for vulnerable populations during the ongoing pandemic and beyond.